/ZYNE
ZYNE Stock - Zynerba Pharmaceuticals, Inc.
Healthcare|Drug Manufacturers - Specialty & GenericNASDAQ
$1.30+2.36%
+$0.03 (+2.36%) • Oct 10
74
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.100
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).70
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.72
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+10.0%upside
Target: $1.43
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for ZYNE
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$1.29 – $1.31
TARGET (TP)$1.49
STOP LOSS$1.20
RISK/REWARD1:1.9
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta1.19
52W High$1.40
52W Low$0.25
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | $86,000 |
| Gross Profit | N/A | N/A | N/A | N/A | $86,000 |
| Gross Margin | N/A | N/A | N/A | N/A | 100.0% |
| Operating Income | $-35,251,540 | $-36,770,390 | $-52,062,542 | $-34,319,810 | $-40,397,830 |
| Net Income | $-34,820,072 | $-37,600,518 | $-50,404,085 | $-31,433,477 | $-39,911,175 |
| Net Margin | N/A | N/A | N/A | N/A | -46408.3% |
| EPS | $-0.82 | $-0.96 | $-1.87 | $-1.43 | $-2.61 |
Company Overview
Zynerba Pharmaceuticals, Inc. operates as a clinical stage specialty pharmaceutical company. The company focuses on developing pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. It is developing Zygel, a pharmaceutically-produced cannabidiol formulated as a permeation-enhanced gel for transdermal delivery. The company was formerly known as AllTranz, Inc. and changed its name to Zynerba Pharmaceuticals, Inc. in August 2014. Zynerba Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Devon, Pennsylvania.
Visit WebsiteLoading analyst ratings...
Earnings History & Surprises
ZYNEBeat Rate
53%
Last 17 quarters
Avg Surprise
+3.5%
EPS vs Estimate
Beats / Misses
9/7
1 met exactly
Latest EPS
$-0.20
Q4 2023
EPS Surprise History
Q1 22
+18.5%
$-0.22vs$-0.27
Q2 22
+4.5%
$-0.21vs$-0.22
Q3 22
-14.3%
$-0.24vs$-0.21
Q4 22
+4.8%
$-0.20vs$-0.21
Q1 23
+25.0%
$-0.18vs$-0.24
Q2 23
-5.0%
$-0.21vs$-0.20
Q3 23
-5.0%
$-0.21vs$-0.20
Q4 23
0.0%
$-0.20vs$-0.20
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q3 2024 | Aug 12, 2024 | — | — | — | — |
Q2 2024 | May 13, 2024 | — | — | — | — |
Q1 2024 | Mar 26, 2024 | — | — | — | — |
Q4 2023 | Nov 13, 2023 | $-0.20 | $-0.20 | 0.0% | = MET |
Q3 2023 | Aug 14, 2023 | $-0.20 | $-0.21 | -5.0% | ✗ MISS |
Q2 2023 | May 15, 2023 | $-0.20 | $-0.21 | -5.0% | ✗ MISS |
Q1 2023 | Mar 28, 2023 | $-0.24 | $-0.18 | +25.0% | ✓ BEAT |
Q4 2022 | Nov 14, 2022 | $-0.21 | $-0.20 | +4.8% | ✓ BEAT |
Q3 2022 | Aug 10, 2022 | $-0.21 | $-0.24 | -14.3% | ✗ MISS |
Q2 2022 | May 16, 2022 | $-0.22 | $-0.21 | +4.5% | ✓ BEAT |
Q1 2022 | Mar 1, 2022 | $-0.27 | $-0.22 | +18.5% | ✓ BEAT |
Q4 2021 | Nov 15, 2021 | $-0.23 | $-0.26 | -13.0% | ✗ MISS |
Q3 2021 | Aug 9, 2021 | $-0.20 | $-0.25 | -25.0% | ✗ MISS |
Q2 2021 | May 12, 2021 | $-0.24 | $-0.20 | +16.7% | ✓ BEAT |
Q1 2021 | Mar 10, 2021 | $-0.38 | $-0.33 | +13.2% | ✓ BEAT |
Q4 2020 | Nov 9, 2020 | $-0.43 | $-0.31 | +27.9% | ✓ BEAT |
Q3 2020 | Aug 10, 2020 | $-0.46 | $-0.78 | -69.6% | ✗ MISS |
Q2 2020 | May 11, 2020 | $-0.49 | $-0.53 | -8.2% | ✗ MISS |
Q1 2020 | Mar 10, 2020 | $-0.48 | $-0.46 | +4.2% | ✓ BEAT |
Q4 2019 | Nov 6, 2019 | $-0.51 | $-0.08 | +84.3% | ✓ BEAT |
Latest News
Loading news...
Frequently Asked Questions about ZYNE
What is ZYNE's current stock price?
Zynerba Pharmaceuticals, Inc. (ZYNE) is currently trading at $1.30 per share. The stock has moved +2.36% today.
What is the analyst price target for ZYNE?
No analyst price targets are currently available for this stock.
What sector is Zynerba Pharmaceuticals, Inc. in?
Zynerba Pharmaceuticals, Inc. operates in the Healthcare sector, specifically within the Drug Manufacturers - Specialty & Generic industry. The company is traded on the NASDAQ exchange.
What is ZYNE's market cap?
Zynerba Pharmaceuticals, Inc. has a market capitalization of $0.07 billion, making it a small-cap company.
Does ZYNE pay dividends?
No, Zynerba Pharmaceuticals, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorAKYA
Akoya Biosciences, Inc.
$1.29
Mkt Cap: $0.1B
BNKK
Bonk, Inc.
$3.94
Mkt Cap: $0.0B
DRRX
DURECT Corporation
$1.91
Mkt Cap: $0.1B
HYFT
MindWalk Holdings Corp.
$1.67
Mkt Cap: $0.1B
IGMS
IGM Biosciences, Inc.
$1.27
Mkt Cap: $0.1B
LIEN
Chicago Atlantic BDC, Inc.
$10.62
Mkt Cap: $0.2B
QNCX
Quince Therapeutics, Inc.
$3.57
Mkt Cap: $0.2B
SURF
Surface Oncology, Inc.
$1.07
Mkt Cap: $0.1B
VLNS
The Valens Company Inc.
$0.76
Mkt Cap: $0.1B
ZOM
Zomedica Corp.
$0.10
Mkt Cap: $0.1B
Explore stocks similar to ZYNE for comparison